Tourmaline went public in 2023 via a reverse merger with the struggling cell therapy developer Talaris. The deal gave Tourmaline funds to develop pacibekitug, an antibody that targets interleukin-6, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback